What is the common examiner trap about Science & Tech in UPSC exams?

They may ask about the prevalence of KRAS mutations, but swap the percentage for pancreatic cancer (~80%) with the percentage for all cancers (~20%) to confuse you. Another trap is asking which cancer the drug is for, but offering 'lung cancer' as a distractor (it's being explored for lung cancer, but the trial results are for pancreatic cancer).

What should UPSC aspirants remember about Science & Tech for Prelims?

1. Target this Data: KRAS mutation is found in approximately 80% of pancreatic cancers. 2. Target this Nodal Body: American Society of Clinical Oncology (ASCO) - where results were presented. 3. Target this Mechanism: Daraxonrasib inhibits the mutated KRAS protein from inside the cell.

Science & TechnologyHealth

Take AI Challenge ▸

News 0 of 25

Daraxonrasib Doubles Survival to 2 Years in Pancreatic Cancer by Targeting KRAS Mutation

Q: The clinical trial results for the drug Daraxonrasib were presented at the annual meeting of which international oncology body?

American Society of Clinical Oncology (ASCO), The article explicitly states that the results from the large international trial were presented at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO is a prominent professional organization for physicians and oncology professionals involved in cancer care and research.

Q: Consider the following statements regarding Daraxonrasib: 1. It is an oral drug that targets the KRAS gene mutation. 2. It has shown to nearly double survival time in patients with advanced pancreatic cancer. 3. KRAS mutations are found in approximately 20% of all cancers. Which of the statements given above is/are correct?

All three, Statement 1 is correct as the article describes Daraxonrasib as a once-daily oral pill that works by targeting the KRAS mutation. Statement 2 is correct as it states the drug nearly doubled survival time in the trial. Statement 3 is correct as the article mentions that mutations in the RAS gene family affect approximately 20% of all cancers. Hence, all three statements are correct.

Q: According to the article, what is the approximate prevalence of KRAS gene mutations in pancreatic cancers?

80%, The article provides a specific figure, stating: "Approximately 80% of pancreatic cancers have alterations in the KRAS gene." Option C (70-90%) is a close distractor as it describes the percentage of patients diagnosed at an advanced stage, not the mutation prevalence.

Q: What is the primary significance of Daraxonrasib's success in the context of cancer treatment research?

It represents a major victory in targeting the previously 'undruggable' KRAS mutation., The article emphasizes that researchers have spent decades trying to effectively shut down KRAS. It describes Daraxonrasib as "the first drug of its class that has shown such successful results" and "a notable triumph in the era of precision oncology." This highlights its significance in overcoming a long-standing challenge, not in replacing other foundational therapies.

Science & Tech Health & Education Social IssuesHIGH

Target:UPSC GS-IIIMPSCTeachingSSC GAPrelims HighMains Medium

03 Jun 2026

~2 min

Source: Indian Express

Key Data:~80% KRAS mutation in pancreatic cancer~20% RAS mutation in all cancersSurvival nearly doubled

Bodies:American Society of Clinical Oncology (ASCO)Tata Memorial Centre

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.Daraxonrasib, a once-daily oral drug, nearly doubled survival time in advanced pancreatic cancer patients in a large international trial.

2.It works by targeting the KRAS gene mutation, a cancer-driving mutation present in ~80% of pancreatic tumours, marking a triumph in precision medicine.

3.The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting, highlighting a potential shift in treatment paradigms for this deadly cancer.

The Big Picture

Prelims · HighMains · Medium

Daraxonrasib, an experimental oral pill, has demonstrated a breakthrough in treating advanced pancreatic cancer by nearly doubling survival time in clinical trials. Its mechanism of targeting the KRAS gene mutation, found in 80% of pancreatic tumours, represents a significant advance in precision oncology after decades of minimal progress.

Exam Lens

Quick Exam Facts From News

Drug NameDaraxonrasib

Target ConditionPancreatic Cancer

Key Target GeneKRAS mutation

Trial Results Presented AtASCO Annual Meeting

KRAS Mutation Prevalence in Pancreatic Cancer~80%

KRAS Mutation Prevalence in All Cancers~20%

1-Minute Revision

›Drug Name: Daraxonrasib
›Target Condition: Pancreatic Cancer
›Target this Data: KRAS mutation is found in approximately 80% of pancreatic cancers.
›Target this Nodal Body: American Society of Clinical Oncology (ASCO) - where results were presented.
›Target this Mechanism: Daraxonrasib inhibits the mutated KRAS protein from inside the cell.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

💊

Breakthrough Pill

Daraxonrasib, an oral pill, nearly doubled survival time in patients with advanced pancreatic cancer in a major trial.

🧬

Precision Oncology

The drug works by targeting and inhibiting the KRAS gene mutation, a key driver found in most pancreatic tumours.

🌍

Global Impact & Access

While not yet available in India, the drug's success signals a new class of treatments for multiple cancers with KRAS mutations.

Detailed Analysis & Strategic Depth

Context / Background

Pancreatic cancer has one of the worst prognoses, with median survival historically hovering around one year despite decades of research. Progress has been minimal due to late-stage diagnosis (70-90% of cases), resistance of the tumour stroma (surrounding tissue), and lack of effective targeted therapies or immunotherapy breakthroughs seen in other cancers.

Core Analysis & Implications

Daraxonrasib's success lies in its novel mechanism: inhibiting the continually active 'ON' state of the mutated KRAS protein from inside the cell. As the first drug in its class to show such efficacy, it validates decades of research aimed at 'drugging' the KRAS target. This opens a new frontier in precision medicine, not just for pancreatic cancer but potentially for the 20% of all cancers driven by RAS mutations, including lung and colon cancers.

Future Outlook / Way Forward

Current trials focus on patients who have failed previous chemotherapy. Future research will explore using daraxonrasib in treatment-naïve patients and in other KRAS-mutant cancers. While accessibility in India is pending, the excitement ensures this class of drugs will soon be evaluated domestically. The breakthrough underscores the need for continued investment in basic cancer biology and precision medicine, working in tandem with traditional therapies like surgery and chemotherapy.

Key Facts at a Glance

Drug NameDaraxonrasib

Target ConditionPancreatic Cancer

Key Target GeneKRAS mutation

Trial Results Presented AtASCO Annual Meeting

KRAS Mutation Prevalence in Pancreatic Cancer~80%

KRAS Mutation Prevalence in All Cancers~20%

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC

The clinical trial results for the drug Daraxonrasib were presented at the annual meeting of which international oncology body?

Q2Statement-basedMediumUPSC

Consider the following statements regarding Daraxonrasib:

1. It is an oral drug that targets the KRAS gene mutation.

2. It has shown to nearly double survival time in patients with advanced pancreatic cancer.

3. KRAS mutations are found in approximately 20% of all cancers.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, SSC

According to the article, what is the approximate prevalence of KRAS gene mutations in pancreatic cancers?

Q4Application/ImpactHardUPSC

What is the primary significance of Daraxonrasib's success in the context of cancer treatment research?

All 20 MCQs ▸

Read original article from Indian Express

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

Science & TechView Topic MCQs →Health & EducationView Topic MCQs →Social IssuesView Topic MCQs →

Next June 3, 1947 Mountbatten Plan Created India & Pakistan Under Independence Act 1947

Related Current Affairs

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Science & Tech Current Affairs

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Science & Tech Current Affairs

Narayana Health Reports Success in Haplo-Cord Transplant for Thalassaemia & Dual-Target CAR-T for Brain Cancer

Doctors at Narayana Health, West Bengal, have successfully treated a 7-year-old thalassaemia patient using a Haplo-cord transplant and a 62-year-old brain cancer patient with dual-target CAR T-cell therapy. These breakthroughs highlight India's growing capability in advanced cell-based therapies and are landmark achievements in treating previously challenging conditions.

Science & Tech Current Affairs

Merck-Moderna's Personalised mRNA Cancer Vaccine Intismeran Reduces Melanoma Death Risk by 49%

A first-of-its-kind personalised mRNA cancer vaccine (intismeran), developed by Merck and Moderna, combined with Keytruda, has shown a 49% reduction in risk of death from melanoma recurrence and 59% from spread in Phase 3 trials. This marks a breakthrough for cancer vaccines but has limited impact in India due to low melanoma incidence and high cost of immunotherapy.

Science & Tech Current Affairs

RK-251: India's ROS-Activated Smart Cancer Drug Could Transform Chemotherapy

RK-251 is a novel 'smart' cancer drug developed by Indian researchers that activates only inside cancer cells using high reactive oxygen species (ROS) levels, potentially reducing chemotherapy side effects. This marks a significant advancement in targeted cancer therapy and is a key topic for UPSC Science & Technology.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Health & Education Current Affairs

WHO's IARC Classifies Hydrochlorothiazide, Voriconazole, Tacrolimus as Group 1 Carcinogens

Three widely used medicines for hypertension, fungal infections, and transplant rejection have been classified as Group 1 carcinogens by WHO's IARC. Patients are warned not to discontinue treatment without consulting doctors, as the classification identifies hazard, not real-world risk at prescribed doses.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Start Today's Quiz(20 Qs)

Take Today's Quiz

20 Qs • 5-7 Mins

Daraxonrasib Doubles Survival to 2 Years in Pancreatic Cancer by Targeting KRAS Mutation

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

Breakthrough Pill

Precision Oncology

Global Impact & Access

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance